Franco-British company Novacyt expressed confidence on Friday ahead of the trial against the UK Department of Health and Social Care (DHSC).

The company, which specializes in molecular diagnostics, points out that the first instance hearing is due to start on June 10 and finish on July 4, but says it expects the court to take its time before passing judgment.

According to Novacyt, this means that the outcome of the trial will not be known as early as July 4.

In the meantime, a discovery hearing will be held on April 30, a process that is customary in litigation and will mainly concern administrative preparations for the trial.

Novacyt points out that the court will occasionally hear a request made by DHSC, which wishes the judgment to be entered for the full value of its claim.

After having obtained legal advice, the company considers that this request is very precarious with little chance of success, and is convinced that the court will reject the request', it writes in a press release.

Following these announcements, Novacyt shares listed on the Paris Bourse were up by almost 7% at mid-day.

Last year, the DHSC decided to lodge a complaint against the Group and its molecular testing subsidiary for failure to complete a supply contract for RNA extraction kits, used in PCR tests for Covid-19.

Following this case, Novacyt in turn lodged a complaint, seeking in particular to recover the sums owed by the DHSC.

Copyright (c) 2024 CercleFinance.com. All rights reserved.